15353-j-veluchamy

126 | Chapter 5 Figure 4: Successful tumor elimination by UCB-NK cells as revealed by bioluminescence imaging in vivo (A) Four mice from control and treatment groups were imaged at day 35 for tumor load and distribution. Mice were injected retro-orbitally with Gluc substrate coelenterazine and images were acquired for 5 min. In SW480 control and SW480+cetuximab groups, tumor growth was extensive and highly disseminated, spreading to most parts of the body. However, in UCB-NK and UCB-NK + cetuximab groups there was a significantly lower tumor load, which was further verified by calculating the average radiance between groups as shown in figure B (n=4 mice per group). (C) Cetuximab functionality against EGFR +++ RAS wt A431 cells was tested in parallel to SW480 studies in BRGS mice (n=3 mice per group). For figures B and C, bars represent mean ± SEM. *P< 0.05 for figure B and figure C was calculated with unpaired t test.